ArticleFrontiers in oncology2022

Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial.

Ying-Jian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.